A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Phase 2 Active not recruiting 238 enrolled Shanghai Miracogen Inc.

RandomizedSequentialOpen-labelTreatment

Summary

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with recurrent metastatic nasopharyngeal carcinoma.

Timeline

Start: 2023-04-06
Primary completion: 2024-12-30
Completion: 2026-12-30

Publications

Han F, Lv X, Zhou YJ, He Q, Guo Y, Xiang YQ, Shu XL, Pan SM, Qu SH, Zhang P, Jiang Y, Xu MJ, Lei KJ, Qu S, Wang XH, Jin YS, Zhao B, Dai R, Wang FH, Xu RH. Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial. Med. 2026 Apr 10;7(4):101029. doi: 10.1016/j.medj.2026.101029. Epub 2026 Feb 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Becotatug Vedotin	Monoclonal antibody	2 mg/kg	Intravenous
Subject	Becotatug Vedotin	Monoclonal antibody	2.3 mg/kg	Intravenous
Comparator	Capecitabine	Small molecule	1000 mg/m2	Oral
Comparator	Docetaxel	Small molecule	75 mg/m2	Intravenous

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Summary

Timeline

Publications

Drugs

Indications